Road Cycling News

Katusha’s Denis Galimzyanov provisionally suspended following positive test for EPO

The Russian WorldTour squad, Katusha, has been rocked by another doping scandal.

Denis Galimzyanov has been provisionally suspended following a positive sample for EPO given during an out-of-competition test last month

Denis Galimzyanov, 25, has been provisionally suspended by his team following a positive test for EPO.

Galimzyanov, overall winner of the green points jersey in last year’s Tour of Beijing and victor on stage five, gave a positive sample in an out-of-competition test last month.

His suspension follows the reinstatement of team-mate, Alexandr Kolobnev, after the UCI lost an appeal to the Court of Arbitration for Sport.

In a statement issued on the UCI’s website, a spokesman for the governing body said: “The UCI advised Russian rider Denis Galimzyanov that he is provisionally suspended.

“The decision to provisionally suspend this rider was made in response to a report from the WADA accredited laboratory in Cologne indicating an Adverse Analytical Finding of EPO in a urine sample collected from him in an out of competition test on 22 March 2012.

“The provisional suspension of Mr Galimzyanov remains in force until a hearing panel convened by the Russian Cycling Federation determines whether he has committed an anti-doping rule violation under Article 21 of the UCI Anti-Doping Rules.

“Mr Galimzyanov has the right to request and attend the analysis of his B sample.”

Galimzyanov won the opening stage of the Circuit de la Sarthe on April 3 , a UCI 2.1 race, and was second on the final stage of the Tour of Qatar behind Arnaud Démare (FDJ-Big Mat).

Last year, he won the Paris-Brussles semi-classic, and the second stage of the Three Days of De Panne.

Galizmyanov’s team-mate Kolobnev left Katusha last year after giving a positive sample for hydrochlorothiazide before the fifth stage of the 2011 Tour De France.

But in March, a CAS panel upheld Kolobnev’s defence that the sample came from prescription medication for a chronic vascular disease, and he was subsequently reinstated by Katusha.

Discuss in the forum

Newsletter Terms & Conditions

Please enter your email so we can keep you updated with news, features and the latest offers. If you are not interested you can unsubscribe at any time. We will never sell your data and you'll only get messages from us and our partners whose products and services we think you'll enjoy.

Read our full Privacy Policy as well as Terms & Conditions.